Therapeutic efficacy and pharmacological mechanism of Yindan Xinnaotong soft capsule on acute ischemic stroke: a meta-analysis and network pharmacology analysis

• Published in: Metabolic brain disease Vol. 39; no. 4; pp. 523 - 543
• Main Authors: Yang, Fangjie, Li, Xinmin, Long, Junzi, Gao, Qian, Pan, Mengyang, Wang, Jing, Zhang, Yasu
• Format: Journal Article
• Language: English
• Published: New York Springer US 01-04-2024; Springer Nature B.V
• Subjects: 1-Phosphatidylinositol 3-kinase; AKT protein; AKT1 protein; Apoptosis; Arteriosclerosis; Atherosclerosis; Biochemistry; Bioinformatics; Biomedical and Life Sciences; Biomedicine; Blood; Chinese medicine; Cholesterol; Encyclopedias; Genomes; Herbal medicine; Ingredients; Ischemia; Lipids; MAP kinase; Meta-analysis; Metabolic Diseases; Molecular docking; Molecular modelling; Neurology; Neuroprotection; Neurosciences; Oncology; Original Article; Pharmacology; Quercetin; Stroke; Traditional Chinese medicine; Viscosity; Traditional Chinese medicine; Network pharmacology; Acute ischemic stroke; Yindan Xinnaotong soft capsule; Meta-analysis
• ISSN: 1573-7365; 0885-7490; 1573-7365
• DOI: 10.1007/s11011-023-01337-w

Yindan Xinnaotong soft capsule (YDXNT), a traditional Chinese medicine preparation, has shown a promising effect in the treatment of acute ischemic stroke (AIS). The goal of this study was to investigate the therapeutic effects and pharmacological mechanisms of YDXNT on AIS. Randomized controlled trials were searched and screened. Review Manager 5.4 was used for a meta-analysis. Active ingredients and targets of YDXNT were extracted from the Traditional Chinese Medicine Systems Pharmacology Database, Bioinformatics Analysis Tool for Molecular mechANism of Traditional Chinese Medicine, and Encyclopaedia of Traditional Chinese Medicine. AIS-related targets were retrieved from GeneCards, OMIM, and DrugBank databases. We constructed PPI and ingredient-target networks, performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses, and conducted molecular docking. The YDXNT group had a higher total effective rate and a higher Barthel Index score. YDXNT reduced the low-density lipoprotein cholesterol and the whole blood viscosity at high and shear rates. Our study identified 313 ingredients and 1196 common targets. The key ingredients were mainly quercetin, neocryptotanshinone II, miltionone I, neotanshinone C, and tanshiquinone B, and the key targets were mainly SRC, MAPK3, AKT1, MAPK1, and JUN. GO analysis showed that the core targets mainly involved in atherosclerosis and neural apoptosis. The core pathways were lipid and atherosclerosis, PI3K-Akt, MAPK, and other pathways. Key ingredients exhibited robust binding interactions with core targets. YDXNT could effectively improve the total effective rate, ability of daily life, blood lipids, and blood viscosity. Antiatherosclerotic and neuroprotective effects are the main pharmacological mechanisms.
Registration number: CRD42023400127.